USPTO serial 79377648
HEALOME THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 30, 2025
- Examiner
- LINDEMYER, ANKHI MUKHERJEA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HEALOME THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicole M. Meyer
Nicole M. Meyer Dickinson Wright PLLC1825 Eye St. N.W., Suite 900Washington, DC 20006United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances and therapeutic pharmaceuticals for diseases, traumatic injury, perioperative care, and inflammation related to the eye; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, lubricants, and ointments used for treatment for ocular diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of eye drops, solutions, gels, lubricants, and ointments used for treatment for ocular diseases, ocular surface diseases and dry eye disease; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of ocular and dermal conditions, sterilized dressings, sprays, and ointments used for treatment for dermal diseases and conditions; pharmaceutical preparations, substances and treatments in the nature of solutions, gels, films impregnated with preparations for the treatment of scars, wounds and orthopaedic conditions, and for use in medical aesthetics treatments, sterilized dressings, sprays, and ointments used for treatment for scar prevention, wound healing, medical aesthetics and orthopaedic conditions; therapeutic preparations and substances, namely, eye drops, ocular lubricants, solutions, gels, films impregnated with preparations for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease, sterilized dressings, sprays, lubricants, and ointments for the treatment of ocular diseases, ocular conditions, ocular surface diseases and dry eye disease; gels for medical eye care; therapeutic gels for medical eye care; gel and liquid drops, sprays, films for use as a delivery agent for drugs and for therapeutic pharmaceuticals, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions, and substances in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, and liquids in the nature of pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of ocular diseases and conditions; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions and diseases; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements in the treatment of ocular conditions; tear film substitutes to provide lubrication, provide protection, support homeostasis, and for use as a delivery agent for drugs and supplements for the treatment of eye conditions and diseases; gels, suspensions, liquids, and lubricants in the nature of pharmaceutical preparations and therapeutic preparations for the treatment of eye conditions, namely, glaucoma, cataracts, amblyopia, age-related macular degeneration and diabetes-related retinopathy; gels, suspensions in the nature of pharmaceutical preparations and therapeutic pharmaceuticals, and liquids for medical and therapeutic use, namely, for treating eye diseases, treating traumatic eye injury, and used in perioperative eye care; eye drops; eye ointment for medical use; medicated eye-washes; eye lotions for medical use; lubricating eye drops; medicated liquids for the treatment of ocular diseases and conditions; medicated ocular lubricants; tear film substitutes being pharmaceutical preparations for the treatment of ocular diseases, injuries and conditions; tear substitutes, namely, artificial tears for ocular diseases and conditions; tear film substitutes, being pharmaceutical preparations in the form of eye drops, solutions, gels, sprays, lubricants, ointments and artificial tears for treatment of ocular diseases and conditions; | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto, namely, scientific research in the field of treatment of eye diseases, injuries and conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; industrial scientific analysis and research services in the fields of eye care products and wound care products; product research and development services; scientific and technological services and research services relating thereto, namely, scientific research in the field of treatment of eye diseases, eye injuries and eye conditions, treatment of dermal diseases, injuries and conditions, and in the field of biomaterials science; scientific research services for medical, biomedical and therapeutic purposes in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; medical and bioscience research services in the fields of ocular surface diseases, dry eye diseases, ocular surface injury, corneal wounds, glaucoma; biomedical research services; scientific research and development services relating to ocular diseases, treatment and conditions; research and development services relating to orthopaedics; scientific research and development services relating to dermatology; scientific research and development services relating to dermal applications, such as scar prevention, wound healing, medical aesthetics; scientific research and development services relating to the treatment of diseases and conditions; scientific research services relating to the treatment of eye diseases and conditions; therapeutic research services, namely, scientific research in the field of eye diseases and eye injury; advisory, consultancy and information services relating to all the aforesaid. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Healome Therapeutics Ltd
- Other trademarks owned by Healome Therapeutics Ltd
- Other trademarks owned by Healome Therapeutics Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named HEALOME THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 6, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 6, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 30, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 30, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 30, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 29, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 11, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 11, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 5, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 10, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 10, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 10, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 10, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 10, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 10, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 10, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 10, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 2, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 15, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 26, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 9, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 9, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 9, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 9, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 9, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 9, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 4, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 4, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 3, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 13, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 13, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 5, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 4, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 28, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 25, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 25, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 25, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 25, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 5, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 31, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |